# Hezhen Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hezhen-medicine

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.healzentx.com
- Latest round: Series B (Nov 27, 2025)
- Investors on record: 2

## About

Founded in 2012 and based in Hangzhou, China, Hangzhou Hezhen Medicine Co., Ltd., dba Hezhen Medicine, integrates drug discovery, process development, and formulation innovation. The company has established research platforms for new drug delivery systems and druggability evaluation, driving innovation in sustained and controlled-release technologies and novel chemical entities. Hezhen Medicine engages in the development of innovative and generic drugs, with expertise in sustained-release formulations and synthesis process optimization. Its product portfolio focuses on immuno-oncology and liver disease therapeutics, supported by in-house R&D, technology transfer, and production capabilities. The company generates revenue from the development and commercialization of proprietary drug formulations, technology transfer, contract research services, and product sales in the biopharmaceutical sector.
In November 2025, Hezhen Medicine closed Series B+ funding led by new investor Qiming Venture Partners.

## Funding rounds

- Series B, Nov 27, 2025 — Qiming Venture Partners
- Series A, Feb 28, 2017 — Liyuan Venture Capital

## Investors

- Liyuan Venture Capital (https://capitalatlas.ai/funds/liyuan-venture-capital) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B